Article Details
Retrieved on: 2025-10-15 18:22:41
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Leerink Partners upped their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here